![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 04, 2023 4:02:49 PM
https://investor.regeneron.com/static-files/dbe7aad3-8aff-483f-9366-fa1678d7b738
Multiple potential FDA submissions: 2023-2025+
DUPIXENT*
Type 2 COPD
LIBTAYO
Adjuvant CSCC
Fianlimab + LIBTAYO
Advanced Melanoma
PRALUENT
Pediatric HeFH (mid)
DUPIXENT*
CPUO
Pozelimab ± cemdisiran+
C5-mediated diseases
Odronextamab
B-Cell NHL (2H)
DUPIXENT*
Bullous Pemphigoid
Garetosmab
FOP
Linvoseltamab
R/R Multiple Myeloma (2H)
Aflibercept 8 mg
RVO
Itepekimab*
COPD
M
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM